Stuttgart - Delayed Quote EUR

AstraZeneca PLC (ZEG.SG)

136.50

+1.50

+(1.11%)

As of 4:14:33 PM GMT+1. Market Open.

Stocks to watch next week: Amazon, Palantir, Disney, Novo Nordisk and AstraZeneca

Earnings preview of key companies reporting next week and what to look out for.

Yahoo Finance UK 5 hours ago

MDLZ

JCI

GOOG
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies

WILMINGTON, Del., January 27, 2025--AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by a Food and Drug Administration (FDA)-approved test, that has progressed on one or more endocrine therapies in the metastatic setting.

Business Wire 3 days ago

AZN

AZNCF
AstraZeneca plans C$820 million (US$570m) investment in Canada to advance growing global hub and clinical delivery

AstraZeneca, a global pharmaceutical company focused on developing life changing medicines, today announced a C$820 million (US$570m) investment in Canada, creating more than 700 high-skilled jobs, across all areas of the business. The investment will support the move to a larger, state-of-the-art office facility in the Greater Toronto Area (GTA), Ontario.

CNW Group 8 days ago

AZN

AZNCF
Trending tickers: Trump Media, Intel, Alibaba, Novo Nordisk and Entain

The latest investor updates on stocks that are trending on Monday.

Yahoo Finance UK 11 days ago

TCEHY

TCTZF

LVMHF
Tariff threats, drug pricing will be 2 key pharma issues during Trump's first year

Trump's second term is bringing back some concerns from his first term, adding pressure to the health sector.

Yahoo Finance 13 days ago

AZN

AZNCF

MRK
Ozempic, Xtandi among next 15 drugs selected for U.S. price talks

The Department of Health and Human Services, through the Centers for Medicare & Medicaid Services, announced the selection of 15 additional drugs covered under Medicare Part D for price negotiations. In accordance with the Inflation Reduction Act, the negotiations with participating drug companies for these 15 drugs will occur in 2025 and any negotiated prices will become effective in 2027, the agency said in a statement. The selected drug list for the second cycle of negotiations is: Novo Nordi

TipRanks 13 days ago

NONOF

NVO

BMY
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer

WILMINGTON, Del., January 17, 2025--DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. The approval by the US Food and Drug Administration (FDA) was based on results from the TROPION-Breast01 Phase III trial.

Business Wire 13 days ago

AZN

AZNCF
Medicare to negotiate prices on 15 drugs, including Ozempic

Medicare seeks to negotiate prices on 15 drugs, including Novo Nordisk's (NVO) GLP-1 weight-loss drugs Ozempic and Wegovy, in new talks. Yahoo Finance senior health reporter Anjalee Khemlani explains the process and the range of other drugs on this new list from pharmaceutical giants Pfizer (PFE), AstraZeneca (AZN), Merck (MRK) To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Luke Carberry Mogan.

Yahoo Finance Video 13 days ago

PFE

MRK

AZN
Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations

Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.

Yahoo Finance 14 days ago

AZN

AZNCF

TEVA
CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma

WILMINGTON, Del., January 17, 2025--AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation.

Business Wire 14 days ago

AZN

AZNCF
Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

WILMINGTON, Del., January 13, 2025--AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) who have received prior systemic therapies, including an EGFR-directed therapy.

Business Wire 18 days ago

AZN

AZNCF
AstraZeneca's (LON:AZN) investors will be pleased with their respectable 55% return over the last five years

AstraZeneca PLC ( LON:AZN ) shareholders might be concerned after seeing the share price drop 11% in the last quarter...

Simply Wall St. last month

AZN

AZNCF
Achilles Therapeutics sells technology assets to AstraZeneca for $12M

Achilles Therapeutics (ACHL) announced that it has transferred the commercial license of data and samples from the TRACERx Non-Small Cell Lung Cancer study to AstraZeneca (AZN). TRACERx, led by Professor Charles Swanton at University College London, UK, is one of the largest tumor evolution studies to generate deep sequencing multi-region and multi-time-point genetic data from over 3,200 tumor samples from over 800 lung cancer patients. As part of the transaction, AstraZeneca will also take over

TipRanks last month

AZN

AZNCF

ACHL
AstraZeneca, Daiichi Sankyo have voluntarily withdrawn a Dato-DXd MAA in EU

AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) have voluntarily withdrawn the marketing authorization application in the EU for datopotamab deruxtecan for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer based on the TROPION-Lung01 Phase 3 trial, the companies announced. “The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency. AstraZeneca and Daiichi

TipRanks last month

AZN

AZNCF
Best paying FTSE 100 stocks of 2024

London-listed firms that have served investors well delivering high yields.

Yahoo Finance UK last month

NWG

AZN

AZNCF
Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Koselugo (selumetinib) for the treatment of paediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)

Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, has entered into a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for Koselugo for the treatment of paediatric patients aged two years and above with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). With the agreement in place with the pCPA, individual provinces and territories may now initiate the process to list Koselugo on their formularies, the timing of wh

CNW Group last month

AZN

AZNCF
LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial

WILMINGTON, Del., December 11, 2024--Updated results from the OlympiA Phase III trial showed AstraZeneca and Merck & Co., Inc’s, known as MSD outside of the US and Canada, LYNPARZA® (olaparib) demonstrated sustained, clinically meaningful improvements in overall survival (OS), invasive disease-free survival (IDFS) and distant disease-free survival (DDFS) at six years for patients with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer.

Business Wire last month

AZN

AZNCF
Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

WILMINGTON, Del., December 09, 2024--Datopotamab deruxtecan (Dato-DXd) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) with disease progression on or after treatment with an EGFR-tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy.

Business Wire last month

AZN

AZNCF
Fixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial

WILMINGTON, Del., December 08, 2024--Positive results from the AMPLIFY Phase III trial showed AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with venetoclax demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukemia (CLL).

Business Wire last month

AZN

AZNCF
Insider Stock Buying Reaches US$2.58m On AstraZeneca

Over the last year, a good number of insiders have significantly increased their holdings in AstraZeneca PLC ( LON:AZN...

Simply Wall St. last month

AZN

AZNCF

Performance Overview

Return	ZEG.SG	FTSE 100
YTD	+7.23%	+6.81%
1-Year	+12.45%	+13.14%
3-Year	+37.33%	+16.18%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AstraZeneca PLC (ZEG.SG)

Stocks to watch next week: Amazon, Palantir, Disney, Novo Nordisk and AstraZeneca

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies

AstraZeneca plans C$820 million (US$570m) investment in Canada to advance growing global hub and clinical delivery

Trending tickers: Trump Media, Intel, Alibaba, Novo Nordisk and Entain

Tariff threats, drug pricing will be 2 key pharma issues during Trump's first year

Ozempic, Xtandi among next 15 drugs selected for U.S. price talks

DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer

Medicare to negotiate prices on 15 drugs, including Ozempic

Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations

CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma

Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

AstraZeneca's (LON:AZN) investors will be pleased with their respectable 55% return over the last five years

Achilles Therapeutics sells technology assets to AstraZeneca for $12M

AstraZeneca, Daiichi Sankyo have voluntarily withdrawn a Dato-DXd MAA in EU

Best paying FTSE 100 stocks of 2024

Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Koselugo (selumetinib) for the treatment of paediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)

LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial

Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

Fixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial

Insider Stock Buying Reaches US$2.58m On AstraZeneca

Performance Overview